JP2015525081A5 - - Google Patents

Download PDF

Info

Publication number
JP2015525081A5
JP2015525081A5 JP2015518597A JP2015518597A JP2015525081A5 JP 2015525081 A5 JP2015525081 A5 JP 2015525081A5 JP 2015518597 A JP2015518597 A JP 2015518597A JP 2015518597 A JP2015518597 A JP 2015518597A JP 2015525081 A5 JP2015525081 A5 JP 2015525081A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
mir
pharmaceutical composition
administration
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015518597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525081A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/046960 external-priority patent/WO2013192486A1/en
Publication of JP2015525081A publication Critical patent/JP2015525081A/ja
Publication of JP2015525081A5 publication Critical patent/JP2015525081A5/ja
Pending legal-status Critical Current

Links

JP2015518597A 2012-06-21 2013-06-21 マイクロｒｎａのｍｉｒ−１５ファミリーの阻害剤 Pending JP2015525081A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662772P 2012-06-21 2012-06-21
US61/662,772 2012-06-21
US201361780352P 2013-03-13 2013-03-13
US61/780,352 2013-03-13
PCT/US2013/046960 WO2013192486A1 (en) 2012-06-21 2013-06-21 Inhibitors of the mir-15 family of micro-rnas

Publications (2)

Publication Number Publication Date
JP2015525081A JP2015525081A (ja) 2015-09-03
JP2015525081A5 true JP2015525081A5 (enExample) 2016-08-12

Family

ID=49769409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015518597A Pending JP2015525081A (ja) 2012-06-21 2013-06-21 マイクロｒｎａのｍｉｒ−１５ファミリーの阻害剤

Country Status (17)

Country Link
US (1) US9163235B2 (enExample)
EP (1) EP2863956A4 (enExample)
JP (1) JP2015525081A (enExample)
KR (1) KR20150036140A (enExample)
CN (1) CN104540527A (enExample)
AR (1) AR091539A1 (enExample)
AU (1) AU2013277033A1 (enExample)
BR (1) BR112014032239A2 (enExample)
CA (1) CA2876105A1 (enExample)
EA (1) EA201590070A1 (enExample)
HK (1) HK1209621A1 (enExample)
IN (1) IN2014DN10899A (enExample)
MD (1) MD20150006A2 (enExample)
MX (1) MX2014015641A (enExample)
SG (1) SG11201408460UA (enExample)
TW (1) TW201406774A (enExample)
WO (1) WO2013192486A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2864482A4 (en) 2012-06-21 2016-02-10 Miragen Therapeutics Inc OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
MX364814B (es) 2013-03-15 2019-05-08 Miragen Therapeutics Inc Nucleosidos biciclicos unidos en puente.
US10443044B2 (en) 2014-04-17 2019-10-15 Ips Heart Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds
WO2016022536A2 (en) 2014-08-04 2016-02-11 MiRagen Therapeutics, Inc. Inhibitors of myh7b and uses thereof
MA40463A (fr) 2014-08-07 2017-06-14 Regulus Therapeutics Inc Ciblage de micro-arn pour traiter des troubles métaboliques
HK1249108A1 (zh) 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
WO2017219170A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
CN106692175A (zh) * 2016-12-26 2017-05-24 大连医科大学附属第二医院 miR‑665‑3p抑制物在制备防治缺血再灌注损伤药物中的应用
US10941403B2 (en) 2018-04-02 2021-03-09 Oregon Health & Science University Microrna inhibitors as anti-cancer therapeutics
JP7692829B2 (ja) 2019-07-30 2025-06-16 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
JP7825881B2 (ja) * 2020-07-23 2026-03-09 ヨハン ヴォルフガング ゲーテ－ウニヴェルズィテート フランクフルト 心不全治療のためのｍｉＲＮＡのコンビナトリアル阻害
CN113599540B (zh) * 2021-05-27 2023-05-23 山西医科大学 miRNA-195-5p在制备抑制或降低麦芽酚铝所致神经细胞损伤的试剂中的应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2428570B1 (en) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
CA2524569C (en) 2002-05-03 2013-10-22 Duke University A method of regulating gene expression
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
ATE546528T1 (de) 2002-11-13 2012-03-15 Univ Jefferson Zusammensetzungen und verfahren zur diagnose und behandlung von krebs
EP2474630B1 (en) 2002-12-20 2016-04-27 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
KR20050115231A (ko) 2003-02-10 2005-12-07 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 포유동물 세포의 조절
US8145436B2 (en) 2003-07-15 2012-03-27 The Trustees Of The University Of Pennsylvania Method and systems for identifying micro-RNA targets and synthesizing novel micro-RNAs and uses of the same
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
EP1676914A4 (en) 2003-09-22 2007-10-10 Aichi Prefecture TYPE OF PATHOLOGICAL LYMPHOMA AND DIAGNOSTIC EVALUATION METHOD
US20080045417A1 (en) 2003-10-14 2008-02-21 Jan Weiler Oligonucleotide Microarray
US20050182011A1 (en) 2003-11-13 2005-08-18 Eric Olson Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
JP4575923B2 (ja) 2003-12-15 2010-11-04 カレッジ オブ メディスン ポーチョン シーエイチエー ユニバーシティ インダストリー−アカデミック コーポレーション ファウンデーション ヒトＥＳ細胞より分離された新規ｍｉＲＮＡ
EP1713938A2 (en) 2004-02-09 2006-10-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
WO2005078096A2 (en) 2004-02-09 2005-08-25 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
CA2556435C (en) 2004-02-13 2014-08-12 The Rockefeller University Anti-microrna oligonucleotide molecules
US8088902B2 (en) 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
US20060134639A1 (en) 2004-04-06 2006-06-22 Huffel Christophe V Method for the determination of cellular transcriptional regulation
US20050260648A1 (en) 2004-04-06 2005-11-24 Huffel Christophe V Method for the determination of cellular transcriptional
DK1735459T3 (da) 2004-04-07 2012-05-29 Exiqon As Fremgangsmåder til kvantificering af microRNA'er og små interfererende RNA'er
EP2471924A1 (en) 2004-05-28 2012-07-04 Asuragen, INC. Methods and compositions involving microRNA
EP2990410A1 (en) 2004-08-10 2016-03-02 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
DK1797183T3 (da) 2004-09-02 2012-10-01 Univ Yale Regulering af onkogener med mikrornas
FR2877350B1 (fr) 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
ES2534300T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US9550990B2 (en) 2004-12-10 2017-01-24 Ionis Pharmaceuticals, Inc. Regulation of epigenetic control of gene expression
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
WO2006071884A2 (en) 2004-12-27 2006-07-06 The Regents Of The University Of Michigan Oligonucleotide based therapeutics
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
US20070065840A1 (en) 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
JP2006292367A (ja) 2005-04-05 2006-10-26 Mitsubishi Rayon Co Ltd ｍｉＲＮＡ検出用マイクロアレイ
WO2006108584A2 (en) 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for cardiovascular disorders and artherosclerosis
EP1874936B1 (en) 2005-04-19 2013-10-30 BASF Plant Science GmbH Improved methods controlling gene expression
DK2002003T3 (en) 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
US20070054287A1 (en) 2005-05-31 2007-03-08 Applera Corporation Method for identifying medically important cell populations using micro rna as tissue specific biomarkers
WO2007053184A2 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
US20090209621A1 (en) 2005-06-03 2009-08-20 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
AU2006279906B2 (en) 2005-08-10 2012-05-10 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
CN101426912A (zh) 2005-08-17 2009-05-06 瑟纳治疗公司 介导rna干扰的化学修饰短干扰核酸分子
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
US20070092882A1 (en) 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
EP1951263A4 (en) 2005-11-21 2009-11-18 Johnson & Johnson Res Pty Ltd MULTITARGETING DISTURBING RNAS WITH TWO ACTIVE STRANDS AND DESIGN AND APPLICATION METHODS
US20070259827A1 (en) 2006-01-25 2007-11-08 University Of Massachusetts Compositions and methods for enhancing discriminatory RNA interference
AU2007212700A1 (en) 2006-01-26 2007-08-16 University Of Massachusetts RNA interference agents for therapeutic use
WO2007092181A2 (en) 2006-01-26 2007-08-16 Unversity Of Massachusetts Compositions and methods for modulating translational repression
EP2388328A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
EP1986697B1 (en) 2006-02-17 2016-06-29 GE Healthcare Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
EP2522748A1 (en) 2006-03-02 2012-11-14 The Ohio State University MicroRNA expression profile associated with pancreatic cancer
CA3042781C (en) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US20080220423A1 (en) 2006-05-19 2008-09-11 Soren Moller Oligonucleotide probes useful for detection and analysis of microRNA precursors
WO2007147067A2 (en) 2006-06-14 2007-12-21 Rosetta Inpharmatics Llc Methods and compositions for regulating cell cycle progression
EP2035446A2 (en) 2006-06-19 2009-03-18 Københavns Universitet (University of Copenhagen) Ribozyme mediated stabilization of polynucleotides
WO2008024499A2 (en) 2006-08-25 2008-02-28 Duke University Methods for in vivo identification of endogenous mrna targets of micrornas
EP2145001A2 (en) 2006-09-19 2010-01-20 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
US20090306181A1 (en) 2006-09-29 2009-12-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
JP2010505427A (ja) 2006-10-09 2010-02-25 ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ）
WO2008147430A2 (en) 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
AU2007323469B2 (en) 2006-11-23 2014-07-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligonucleotides for modulating target RNA activity
EP2102341A2 (en) 2006-12-08 2009-09-23 Asuragen, INC. Mirna regulated genes and pathways as targets for therapeutic intervention
WO2008073921A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-126 regulated genes and pathways as targets for therapeutic intervention
EP2104737B1 (en) 2006-12-08 2013-04-10 Asuragen, INC. Functions and targets of let-7 micro rnas
EP2104735A2 (en) 2006-12-08 2009-09-30 Asuragen, INC. Mir-21 regulated genes and pathways as targets for therapeutic intervention
US20090137504A1 (en) 2006-12-21 2009-05-28 Soren Morgenthaler Echwald Microrna target site blocking oligos and uses thereof
EP3536788A1 (en) 2006-12-21 2019-09-11 QIAGEN GmbH Microrna target site blocking oligos and uses thereof
CA2671270A1 (en) 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
WO2008109373A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
US9043994B2 (en) 2007-03-13 2015-06-02 Massachusetts Institute Of Technology Cre-lox based gene knockdown constructs and methods of use thereof
WO2008116267A1 (en) 2007-03-26 2008-10-02 Crc For Asthma And Airways Ltd Therapeutic targets and molecules
WO2008147839A1 (en) 2007-05-23 2008-12-04 Dharmacon, Inc. Micro-rna scaffolds and non-naturally occurring micro-rnas
WO2009012263A2 (en) 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
BRPI0813527A2 (pt) 2007-07-18 2014-12-30 Univ Colorado Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham
US20090092980A1 (en) 2007-07-20 2009-04-09 Christoph Arenz miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES
WO2009044895A1 (ja) 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 標的遺伝子の発現を抑制する組成物
DK2205737T3 (da) 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
US8389485B2 (en) 2007-10-29 2013-03-05 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
WO2009062169A2 (en) 2007-11-09 2009-05-14 The Board Of Regents Of The University Of Texas System Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
EP2520649A3 (en) * 2007-11-23 2013-02-20 Panagene, Inc. MicroRNA antisense PNAs, compositions comprising the same, and methods for using and evaluating the same
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES
EP2105145A1 (en) 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
US20090326049A1 (en) 2008-04-04 2009-12-31 Alexander Aristarkhov Blocking oligos for inhibition of microrna and sirna activity and uses thereof
US20100113284A1 (en) 2008-04-04 2010-05-06 Alexander Aristarkhov Small interfering rna (sirna) target site blocking oligos and uses thereof
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
CA2726052A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
WO2010036939A2 (en) 2008-09-26 2010-04-01 University Of Southern California A system for synergistic expression of multiple small functional rna elements
EP2447274B1 (en) 2008-10-24 2017-10-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds and methods
WO2010126355A1 (en) 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
MA33488B1 (fr) 2009-06-08 2012-08-01 Miragen Therapeutics Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn

Similar Documents

Publication Publication Date Title
JP6208228B2 (ja) ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
JP2015521626A5 (enExample)
EP2759595B1 (en) Composition comprising an encapsulated antagomir
US20120122953A1 (en) Methods for enhancing utrophin production via inhibition of microrna
US9163235B2 (en) Inhibitors of the miR-15 family of micro-RNAs
ES3001019T3 (es) Inhibidores del MICRO-RNA 22
JP2018521669A (ja) 治療用オリゴヌクレオチド
Liu et al. Systemic delivery of microRNA for treatment of brain ischemia
ES2781459T3 (es) Oligonucleótidos terapéuticos
JP2016518820A5 (enExample)
EP3347470B1 (en) Sirna and their use in methods and compositions for inhibiting the expression of the nrarp gene
EP2968396A1 (en) Locked nucleic acid inhibitor of mir-145 and uses thereof
WO2023023662A1 (en) Targeting oncogenic kras with molecular brush-conjugated antisense oligonucleotide
WO2024124315A1 (en) Antisense oligonucleotide analogs of mir-29 and uses thereof
CN110141577A (zh) miRNA-24-3p核苷酸类似物在制备药物中的应用
US20240327830A1 (en) Dise-inducing srna-polyplexes and srna-lipopolyplexes and methods of using the same to treat cancer
JP2024057599A (ja) マイクロｒｎａ２２の阻害剤
CN121371192A (zh) 制备工程化外泌体与微小rna药物的结合物的方法、结合物及其应用
CN104470543A (zh) 梗塞治疗用医药组合物
BR112018001782B1 (pt) Oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica
BR122024021791A2 (pt) Oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica
HK1257658B (en) Sirna and their use in methods and compositions for inhibiting the expression of the nrarp gene